Business

Know the Business

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Reckitt is a portfolio of trusted brand monopolies — Lysol, Dettol, Mucinex, Durex, Finish, Mead Johnson Nutrition — that earn 60%+ gross margins by selling cheap, frequently-bought products at premium prices in categories where consumers refuse to trade on hygiene, intimate health, or what they give a baby. The investment debate is not whether the brands have power; it is whether management can keep the price/mix engine running in a developed world where volumes are flat and Europe is shrinking, while resolving the unfinished question of what to do with Mead Johnson Nutrition. After the December 2025 disposal of Essential Home (laundry/surface care to Advent), the group is now meant to be a "Core Reckitt + MJN" business — but the simplification only matters if Emerging Markets keeps compounding at the FY2025 LFL rate of +14.6%.

1. How This Business Actually Works

Reckitt sells small, high-frequency consumables — a $5 throat lozenge pack, a $8 dishwasher tablet box, a $4 antiseptic bottle — through global retailers and emerging-market distributors. The economic engine is not unit volume; it is the gap between gross margin and brand investment, which funds innovation that lets the company keep raising price faster than cost.

Three things follow from this structure. First, gross margin is the moat metric. Group gross margin of 60.8% (Core Reckitt 62.2%) is the highest in the household & personal products peer set, and management is explicit that they are not trying to push it higher — the surplus funds reinvestment, not earnings beats. Second, brand equity investment (BEI) — 14.6% of revenue in 2025, up from 13.4% — is the price the moat charges. If BEI ever drifts down to manufacture EPS, the brands quietly weaken. Third, fixed costs (19.4% of revenue, declining under the "Fuel for Growth" cost programme) are the only line management can flex; below the gross margin line, this is essentially a cost-discipline story.

The Powerbrand model is a lattice, not a list. Eleven brands cover four categories — Self Care (Mucinex, Nurofen, Strepsils, Gaviscon), Germ Protection (Lysol, Dettol, Harpic), Household Care (Finish, Vanish), Intimate Wellness (Durex, Veet) — plus Mead Johnson Nutrition's Enfamil/Nutramigen franchise. The company runs a "Winning Playbook" that pushes three levers across each brand: household penetration (more SKUs, more channels), premiumisation (Durex Intensity nitrile, Finish Ultimate Plus), and category creation (Lysol Laundry Sanitizer reportedly grew to ~$400m of retail sales as a new sub-category).

The FY2025 mix tells the real story: Intimate Wellness (+12.5% LFL) and Germ Protection (+8.4% LFL) are growing fast; Household Care is flat; Self Care is held back by Mucinex/Strepsils season weakness. Mead Johnson at +3.8% LFL has stabilised but is still a separate strategic question — management said they continue to "assess long-term strategic options."

The geographic split is the real competitive map. Europe and North America together throw off ~31% margins on roughly flat revenue; Emerging Markets is growing volume and price/mix in roughly equal measure (+6.7% / +7.9%) at a 20.9% margin that has expanded 210bps in the year. The bear case for the next five years is that developed-market margins compress (Europe is openly described by management as "a tough marketplace") faster than emerging-market scale builds. The bull case is that Emerging Markets is now 42% of Core Reckitt and converging upward.

2. The Playing Field

Reckitt is a top-tier global household & personal-products name, sized between Colgate-Palmolive and Unilever, but with a profile that is closer to a consumer-health pure-play (Haleon, Kenvue) than to a paper/diaper business (Kimberly-Clark) or a laundry/beauty conglomerate (P&G).

Reckitt P/E uses adjusted FY2025 diluted EPS of $4.75 (352.8 pence × 1.3466); the IFRS $6.29 figure is inflated by the ~$1,677m gain on the Essential Home disposal. Peer figures are TTM USD.

Two facts jump off the peer table. First, Reckitt's gross margin (60.8%) sits at the top of the set, statistically tied with Haleon (consumer health) and ahead of Colgate, P&G, KMB, Unilever — proof that the Powerbrand thesis is actually monetised at the gross line, not just claimed in marketing. Second, Reckitt trades at the cheapest EV/EBITDA in the peer set (~9x) despite a top-quartile operating margin. The market is pricing this as either a structurally lower-quality compounder than P&G/Colgate, or as a stock with unresolved overhangs — the most obvious of which is Mead Johnson Nutrition. A young analyst should not assume this gap closes; it should be the centre of the thesis.

What "good" looks like in this peer set: P&G is the operational benchmark — superior brand portfolio breadth, deeper retailer relationships, a 24%+ adj. operating margin at three times Reckitt's revenue, and the multiple to prove it. Reckitt's structural answer is to look more like Haleon — a focused consumer-health play at the top of the gross-margin distribution, with growth concentrated in pricing power and emerging-market penetration rather than developed-market volume.

3. Is This Business Cyclical?

Branded household and consumer-health products are textbook "defensives" — but Reckitt's eleven-year P&L shows that the cyclicality is real, just unconventional. The cycle hits this business through three distinct channels: cold-and-flu seasons, emerging-market currency, and large-acquisition impairment cycles — not through GDP.

The two negative-margin years tell most of the story. FY2019: a ~$6.7bn goodwill impairment on the IFCN (now Mead Johnson Nutrition) cash-generating unit acquired for $17.9bn in 2017 — the cycle that hit was the China premium-formula market collapse plus declining birth rates, which structurally devalued the asset. FY2021: a further round of impairments on the same business as the post-COVID hygiene boom faded and infant nutrition stayed weak. FY2020 itself: revenue spiked +6% on Lysol/Dettol/Finish demand during COVID; margins did not, because the company chose to reinvest aggressively rather than let the boom drop to the bottom line. FY2022–2025: a steady recovery, with FY2025's IFRS jump to 29.7% an artefact of the ~$1,677m gain on the Essential Home disposal, not operational outperformance.

The takeaway: Reckitt's volume cycle is mild but its margin and earnings cycle is large, dominated by management decisions on M&A and impairments rather than by consumer-spend cycles. A young analyst should treat the next big M&A move as the most important macro variable for this stock — bigger than UK or Eurozone GDP.

4. The Metrics That Actually Matter

The ratios that move the stock here are not the textbook ones. Headline P/E and dividend yield are misleading because IFRS profit is dominated by impairments and disposal gains. The five metrics below are what matters for understanding whether the brand-funded reinvestment engine is working.

Why these specifically:

• LFL net revenue growth split into volume and price/mix, by area. The Core Reckitt FY2025 split (+1.5% volume / +3.7% price/mix) is structurally healthy; if price/mix exceeds 5% with negative volumes for two years running, the brands are overpricing themselves and a Unilever-style volume reset is coming.
• Gross margin held above 60%. This is the single best test of the moat. A drift toward 58% would imply private-label or category-mix erosion that BEI cannot offset.
• BEI as % of revenue. Reckitt's history shows margin can be manufactured by cutting BEI, but only at the cost of next year's market share. A young analyst should be deeply suspicious of any margin beat that coincides with a BEI cut.
• Top-CMU share holding/gaining. This is the closest thing to a real-time moat indicator. The 51% in FY2025 (vs 55% in FY2024) is a yellow light, attributable mainly to a soft cold/flu season.
• ROCE around 14%. This is the bottom of the global staples range; most of the gap to P&G and Colgate is due to the Mead Johnson Nutrition asset still on the balance sheet at acquisition value.
• FCF conversion. The drop from 91% to 71% is the metric to monitor most closely in FY26 — it reflects restructuring spend and cash tax, both of which should be transient. If conversion stays below 80% in FY26, the bull case meaningfully weakens.

5. What I'd Tell a Young Analyst

Reckitt is a high-quality brand business priced at a low-quality multiple, for two reasons that are real but knowable.

First: the IFRS numbers are noise. FY2025 reported operating profit of ~$5,679m looks like a 75% jump on FY2024's ~$3,038m — but ~$1,677m was the gain on Essential Home, ~$337m was an offsetting Biofreeze impairment, and ~$241m was restructuring. Adjusted operating profit grew 5.3%. The market knows this. Build your model on adjusted figures and on Core Reckitt LFL growth — that is the operating reality.

Second: Mead Johnson Nutrition is the unspoken thesis. It is 15% of group revenue, was acquired for $17.9bn in 2017, has been written down by roughly $19bn cumulatively, contributes a 20.4% margin (well below Core Reckitt's 26.7%), and its "strategic options remain under review." Whether MJN is sold, spun, or retained is the single biggest variable in the multiple. A separation at any reasonable valuation would re-rate Core Reckitt toward the Haleon multiple (13–14x EV/EBITDA) from the current ~9x.

What I would actually watch, week to week:

• Cold and flu surveillance data in the US and Europe. Mucinex and Strepsils are large enough to swing 50–100bps of group margin in a soft season; the Q4 2025 weakness was almost entirely seasonal.
• Emerging-markets FX drag versus LFL. A -3.7% FX hit on +14.6% LFL is the FY2025 ratio. If the FX drag widens to -5% or more, the IFRS top line goes flat even with strong execution.
• BEI line as % of net revenue, every half year. 14.6% is the floor. If BEI drops below 14% to support an EPS guide, take it as a signal that something is wrong inside the brand portfolio, not as good cost discipline.
• Any commentary on MJN process or buyer interest. This is the single biggest catalyst. Pay attention to industry meetings, China formula tender results, and any private-equity infant-nutrition rumours.
• Capex. Stepped up to ~$797m in 2025, with North Carolina, China (Taicang/Shanghai), Poland (Finish), and Thailand (Gaviscon) all in flight. The thesis assumes this is on-strategy and on-budget. A miss here would be a serious challenge to the supply-chain credibility CEO Kris Licht has built since 2024.

What would change the thesis: a clean exit from MJN at a defensible value; sustained Core Reckitt LFL above 5% with Emerging Markets at +12%+ for two more years; gross margin held above 60% through input-cost normalisation. What would break it: a third write-down on MJN; BEI falling under 14% to manufacture EPS; price/mix above 5% with volumes negative for two years; ROCE failing to clear 15% by FY2027.

Reckitt is not Procter & Gamble. It does not need to be. It needs to be a focused, top-decile-margin consumer-health business that compounds price/mix in emerging markets and resolves its one big legacy problem. If you can answer "is MJN still on the balance sheet at year-end 2027?" you have answered most of the stock.